Takeda reported that its oral TYK2 inhibitor zasocitinib (TAK-279) beat Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a head-to-head Phase 3 readout for moderate-to-severe plaque psoriasis. The company said the trial met statistical superiority and reported higher rates of complete skin clearance. Takeda indicated it plans to file with the FDA and other regulators starting this fiscal year. The outcome places zasocitinib as a competitive second entrant into an oral psoriasis market already validated by the first-in-class competitor. Regulatory and payer discussions are likely to hinge on the magnitude and durability of the clearance curves and how zasocitinib’s selectivity profile translates into safety and tolerability versus the incumbent.